# EDGAR Filing Document

**Accession Number:** 0001610820
**File Stem:** 0001493152-23-004295
**Filing Date:** 2023-2
**Character Count:** 9059
**Document Hash:** 1f4bc428498c1ea07bf38a54fd35e5e5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-004295.hdr.sgml**: 20230210

**ACCESSION NUMBER**: 0001493152-23-004295

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230209

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230210

**DATE AS OF CHANGE**: 20230210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BriaCell Therapeutics Corp.
- **CENTRAL INDEX KEY:** 0001610820
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40101
- **FILM NUMBER:** 23612539

**BUSINESS ADDRESS:**
- **STREET 1:** 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
- **CITY:** WEST VANCOUVER
- **STATE:** A1
- **ZIP:** V7T 2X1
- **BUSINESS PHONE:** (604) 921-1810

**MAIL ADDRESS:**
- **STREET 1:** 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
- **CITY:** WEST VANCOUVER
- **STATE:** A1
- **ZIP:** V7T 2X1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ansell Capital Corp.
- **DATE OF NAME CHANGE:** 20140613

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 9, 2023

---

| |
|:---|
| **BRIACELL THERAPEUTICS CORP.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **British Columbia** | **47-1099599** |
| (State or other jurisdiction<br> of incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **Suite 300 - 235 15th Street**<br> **West Vancouver, BC V7T 2X1** | **V7T 2X1** |
| (Address of principal executive offices) | (Zip Code) |

---

(604) 921-1810

(Registrant's telephone number, including area code)

Commission File No. 001-40101

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered under Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Shares, no par value | BCTX | The Nasdaq Stock Market LLC |
| Warrants to purchase common shares, no par value | BCTXW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

On February 9, 2023, the Company issued a press release announcing the preliminary results of its Annual Meeting. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

**EXHIBIT INDEX**

<u>Exhibit</u> <u>Description</u> <br> 99.1 [Press Release](ex99-1.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | BRIACELL THERAPEUTICS CORP. |
|  | */s/ William V. Williams* |
| February 10, 2023 | William V. Williams |
|  | President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**BRIACELL THERAPEUTICS CORP. ANNOUNCES RESULTS OF SHAREHOLDER MEETING** 

PHILADELPHIA, PA and VANCOUVER, British Columbia, February 9, 2023 **– BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company")**, a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the "**Shareholders**") for the year ended July 31, 2022 held on February 9, 2023 (the "**Meeting**"). A total of 6,663,370 common shares of the Company (the "**Common Shares**") were voted, representing 42.94% of the Company's issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions that consisted of the following:

&nbsp;&nbsp;&nbsp;&nbsp;1. Appointment
 of MNP LLP as auditors of the Company for the ensuing year and authorizing the directors
 to fix their remuneration;

2. Election
 of Dr. William V. Williams, Mr. Jamieson Bondarenko, Mr. Marc Lustig, Dr. Jane A. Gross,
 Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin E. Schmieg as directors of
 the Company;

3. Approval
 of the Company's new omnibus equity incentive plan (the "**Omnibus Plan** ");

4. Ratification
 of restricted share units awarded under the Omnibus Plan; and

5. Approval
 and adoption of an amendment to the Articles of the Company to require the presence, in person
 or by proxy, of two or more shareholders representing at least 33 1/3% of the outstanding
 shares entitled to be voted in order to constitute a quorum at any meeting of shareholders,
 and to remove the quorum exception for succeeding meetings of shareholders.

Having received Shareholder approval, the Company's Omnibus Plan remains subject to final approval from the Toronto Stock Exchange. The formal report on voting results with respect to all matters voted upon during the Meeting will be filed on the Company's SEDAR profile at <u>www.sedar.com</u>.

**About BriaCell Therapeutics Corp.**

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at <u>https://briacell.com/</u>.

**Safe Harbor**

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at **<u>www.sedar.com</u>** and on EDGAR at **<u>www.sec.gov</u>**. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

**Contact Information**

**Company Contact:**<br> William V. Williams, MD

President & CEO<br> 1-888-485-6340<br> <u>info@briacell.com</u>

**Media Relations:**<br> Jules Abraham<br> Director of Public Relations<br> CORE IR<br> 917-885-7378<br> <u>julesa@coreir.com</u>

**Investor Relations Contact:**<br> CORE IR<br> <u>investors@briacell.com</u>